Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.

The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.

MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

Some British people are turning to unregulated weight loss medications sold online as drug prices climb and prescription waits lengthen.

Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.

Cell and gene therapies (CGTs) have immense potential, but there are considerable challenges with logistics and storage that must be thoroughly understood and managed.

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.